Limits...
EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy

View Article: PubMed Central - PubMed

ABSTRACT

Purpose: The aim of this research was to examine the molecular and clinical features that are related with EGFR-tyrosine kinase inhibitor (EGFR-TKI) efficacy in previously treated patients with squamous cell carcinoma of the lung (SCCL).

Materials and methods: This retrospective study included 67 SCCL patients with obtainable lung cancer tissue and records on EGFR-TKI treatment response and survival. EGFR protein expression in lung cancer tissue was measured by immunohistochemistry with a specific antibody that recognizes the intracellular domain (ID) of EGFR. PTEN expression in lung cancer tissue was also evaluated with immunohistochemistry. PI3KCA gene amplification was detected by quantitative real-time polymerase chain reaction, and FGFR1 amplification was assessed by fluorescent in situ hybridization.

Results: EGFR ID expression (hazard ratio [HR] 0.53, P=0.022) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) (HR 0.43, P=0.022) were significantly related with progression-free survival following EGFR-TKIs treatment. PTEN expression (HR 0.52, P=0.025) was significantly related to overall survival. The group of EGFR-positive or PTEN-positive patients with ECOG PS of 0 or 1 had better clinical outcomes than patients who were EGFR-negative and PTEN-negative or who had poor ECOG PS with longer median progression-free survival (2.1 vs 1.0 months, P=0.05) and overall survival (6.2 vs 2.1 months, P=0.05).

Conclusion: EGFR expression using an ID-specific antibody and PTEN protein expression may be used to identify SCCL patients who might benefit from EGFR-TKI treatment.

No MeSH data available.


Related in: MedlinePlus

Overall survival curves of the two groups according to ECOG PS, PTEN and EGFR ID.Notes: (A) ECOG PS, (B) PTEN expression, and (C) the combined criteria of ECOG PS, EGFR ID expression, and PTEN expression in patients with advanced squamous cell lung cancer who were receiving gefitinib or erlotinib as second-line or higher therapy.Abbreviations: ECOG, Eastern Cooperative Oncology Group; ID, intracellular domain; OS, overall survival; PS, performance status.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4998034&req=5

f2-ott-9-5153: Overall survival curves of the two groups according to ECOG PS, PTEN and EGFR ID.Notes: (A) ECOG PS, (B) PTEN expression, and (C) the combined criteria of ECOG PS, EGFR ID expression, and PTEN expression in patients with advanced squamous cell lung cancer who were receiving gefitinib or erlotinib as second-line or higher therapy.Abbreviations: ECOG, Eastern Cooperative Oncology Group; ID, intracellular domain; OS, overall survival; PS, performance status.

Mentions: Analysis of OS revealed that PTEN expression and ECOG PS were significantly related to OS (Figure 2). In the multivariate analysis of OS, patients with PTEN expression were at a lower risk of death than PTEN-negative patients (HR 0.52, 95% CI: 0.30–0.93, P=0.025) (Table 2). ECOS PS of 0 or 1 showed borderline statistical significance (HR 0.59, 95% CI: 0.35–1.0, P=0.053) (Table 2). Neither PI3KCA amplification nor FGFR1 amplification was related with PFS or OS.


EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
Overall survival curves of the two groups according to ECOG PS, PTEN and EGFR ID.Notes: (A) ECOG PS, (B) PTEN expression, and (C) the combined criteria of ECOG PS, EGFR ID expression, and PTEN expression in patients with advanced squamous cell lung cancer who were receiving gefitinib or erlotinib as second-line or higher therapy.Abbreviations: ECOG, Eastern Cooperative Oncology Group; ID, intracellular domain; OS, overall survival; PS, performance status.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4998034&req=5

f2-ott-9-5153: Overall survival curves of the two groups according to ECOG PS, PTEN and EGFR ID.Notes: (A) ECOG PS, (B) PTEN expression, and (C) the combined criteria of ECOG PS, EGFR ID expression, and PTEN expression in patients with advanced squamous cell lung cancer who were receiving gefitinib or erlotinib as second-line or higher therapy.Abbreviations: ECOG, Eastern Cooperative Oncology Group; ID, intracellular domain; OS, overall survival; PS, performance status.
Mentions: Analysis of OS revealed that PTEN expression and ECOG PS were significantly related to OS (Figure 2). In the multivariate analysis of OS, patients with PTEN expression were at a lower risk of death than PTEN-negative patients (HR 0.52, 95% CI: 0.30–0.93, P=0.025) (Table 2). ECOS PS of 0 or 1 showed borderline statistical significance (HR 0.59, 95% CI: 0.35–1.0, P=0.053) (Table 2). Neither PI3KCA amplification nor FGFR1 amplification was related with PFS or OS.

View Article: PubMed Central - PubMed

ABSTRACT

Purpose: The aim of this research was to examine the molecular and clinical features that are related with EGFR-tyrosine kinase inhibitor (EGFR-TKI) efficacy in previously treated patients with squamous cell carcinoma of the lung (SCCL).

Materials and methods: This retrospective study included 67 SCCL patients with obtainable lung cancer tissue and records on EGFR-TKI treatment response and survival. EGFR protein expression in lung cancer tissue was measured by immunohistochemistry with a specific antibody that recognizes the intracellular domain (ID) of EGFR. PTEN expression in lung cancer tissue was also evaluated with immunohistochemistry. PI3KCA gene amplification was detected by quantitative real-time polymerase chain reaction, and FGFR1 amplification was assessed by fluorescent in situ hybridization.

Results: EGFR ID expression (hazard ratio [HR] 0.53, P=0.022) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) (HR 0.43, P=0.022) were significantly related with progression-free survival following EGFR-TKIs treatment. PTEN expression (HR 0.52, P=0.025) was significantly related to overall survival. The group of EGFR-positive or PTEN-positive patients with ECOG PS of 0 or 1 had better clinical outcomes than patients who were EGFR-negative and PTEN-negative or who had poor ECOG PS with longer median progression-free survival (2.1 vs 1.0 months, P=0.05) and overall survival (6.2 vs 2.1 months, P=0.05).

Conclusion: EGFR expression using an ID-specific antibody and PTEN protein expression may be used to identify SCCL patients who might benefit from EGFR-TKI treatment.

No MeSH data available.


Related in: MedlinePlus